Coming to A Neighborhood Near You: Making Early Disease Screening Ubiquitous
We are removing barriers to disease screening, dramatically increasing the number of people participating in recommended programs. As patient screening volume increases, early detection of asymptomatic patients will also increase, allowing for earlier intervention and disease management.
Our sampling technology can be placed in doctors’ offices, pharmacies, and even mobile units, providing accessible early-detection options for all populations. All you have to do is breathe: no needles, no contrast, and no radiation.
We're Starting with Lung Cancer, the Deadliest Cancer in the U.S. and the World.
Annual screening is recommended for 14 million Americans who are at high risk for developing lung cancer. However, only approximately 5% of those eligible get screened for lung cancer. The current screening standard is low-dose computed tomography scan (LDCT). Breathe BioMedical is working to increase the number of those screened by removing common barriers:
Nearly one-third of Americans live more than 30 miles from an LDCT machine.
Our breath sampler is compact and portable, allowing deployment in accessible point of care locations.
Exposure to radiation gives pause for asymptomatic individuals and health care providers.
Our approach to sampling is non-invasive without any exposure to radiation.
LDCT instruments are large, complex and expensive, requiring specialized staff and facilities.
Our point of care technology is less expensive and can be administered by non-technical staff.